alexa
Reach Us +443308085114
Systematic Shortlisting Of Candidate Molecules And Biosimilar/biobetter Product Development: An Undergraduate Research Effort | 58648
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Systematic shortlisting of candidate molecules and biosimilar/biobetter product development: An undergraduate research effort

6th International Conference on Biologics & Biosimilars

Balram Pani, Pooja Gupta, Ranjeet S Thakur, Avneesh Mittal, Purnima Anand, Deepika Bhaskar and Uma Chaudhry

Bhaskaracharya College of Applied Sciences- University of Delhi, India

ScientificTracks Abstracts: J Bioanal Biomed

DOI: 10.4172/1948-593X.C1.023

Abstract
Pioneered at Stanford University in the 1970s, the recombinant DNA technology has made possible the modern biopharmaceutical industry. Biotherapeutics have revolutionised the treatment of various life-threatening and chronic conditions, but they are very expensive and therefore remain out of the reach of millions across the world. As these products lose patent protection, follow-on biologics like biosimilars and biobetters are poised to drastically expand patient access by increasing affordability. India, already home to a robust generics industry, also has multiple players developing as well as manufacturing biosimilars for both the domestic and global markets. In order to identify potential biotherapeutics for biosimilar development, we manually annotated the US-FDA CDER and CBER lists, extracted biologics with therapeutic applications in humans, classified these on the basis of their patent status and biomolecule categories, and then checked which ones had comparable biosimilars in the Indian market. Since the objective was to use a microbial expression system, we further eliminated products with extensive post-translational modifications, and arrived at enzyme candidates like asparaginase, collagenase, and monoclonal antibody candidates like Ranibizumab. Asparaginase, indicated for the treatment of acute lymphoblastic leukemia, was expressed in E. coli, purified and was assayed in the CEL and Kasumi cell lines. Its physicochemical biosimilarity with the reference product was also established. In the next phase of our study, cysteine-specific PEGylation of the ranimizumab Fab’ fragment (expressed in E. coli) would be carried out in an attempt to develop a biobetter version of the same (PEGylation improves efficacy, stability and antigenicity).
Biography

Balram Pani, the Principal of Bhaskaracharya College of Applied Sciences, is also a faculty in the Department of Chemistry, University of Delhi. He obtained his PhD from Jawaharlal Nehru University. He has 20 years of research and teaching experience in the field of Chemistry and Environmental Science. He has also authored various books on Environmental Science and Engineering Chemistry, which have been adopted by several universities, and Engineering and Science Colleges.

Email: [email protected]

Top